Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERO CERo Therapeutics	$10.68 -4.6%	$12.11	$6.71 ▼ $895.40	$4.32M	0.41	305,730 shs	255,560 shs
CGIX Cancer Genetics	$0.19	$0.26	$2.11 ▼ $17.50	$792K	2.72	2.44 million shs	19,116 shs
PSTV Plus Therapeutics	$0.37 +16.4%	$0.46	$0.16 ▼ $2.31	$5.35M	0.64	9.73 million shs	168.08 million shs
VERO Venus Concept	$2.20 +0.9%	$2.42	$2.10 ▼ $14.50	$3.11M	0.07	607,188 shs	33,125 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERO CERo Therapeutics	-4.56%	-7.13%	+2.50%	-28.89%	-98.14%
CGIX Cancer Genetics	0.00%	0.00%	0.00%	0.00%	0.00%
PSTV Plus Therapeutics	+16.38%	+81.04%	+25.94%	-68.40%	-75.06%
VERO Venus Concept	+0.92%	-8.71%	-4.35%	-20.00%	-75.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CERO CERo Therapeutics	3.4332 of 5 stars	3.7	3.0	0.0	0.0	2.4	0.8	0.0
CGIX Cancer Genetics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	2.4753 of 5 stars	3.3	4.0	0.0	0.0	3.1	0.0	0.6
VERO Venus Concept	3.0171 of 5 stars	0.0	5.0	0.0	0.0	4.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERO CERo Therapeutics	3.33	Buy	$45.00	321.35% Upside
CGIX Cancer Genetics	0.00	N/A	N/A	N/A
PSTV Plus Therapeutics	2.50	Moderate Buy	$11.67	3,082.40% Upside
VERO Venus Concept	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CGIX, VERO, CERO, and PSTV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	PSTV Plus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.50 ➝ $3.00
6/25/2025	PSTV Plus Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$9.00
6/23/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/23/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
6/5/2025	PSTV Plus Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $20.50
5/30/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/30/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/19/2025	CERO CERo Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/5/2025	PSTV Plus Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/5/2025	PSTV Plus Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/22/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	($41.98) per share	N/A
CGIX Cancer Genetics	$6.33M	0.13	N/A	N/A	N/A	∞
PSTV Plus Therapeutics	$5.82M	1.07	N/A	N/A	($1.52) per share	-0.24
VERO Venus Concept	$64.83M	0.05	N/A	N/A	$4.30 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERO CERo Therapeutics	-$8.30M	N/A	0.00	∞	N/A	N/A	N/A	-199.71%	8/13/2025 (Estimated)
CGIX Cancer Genetics	N/A	-$2.07	N/A	∞	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	-$12.98M	-$2.94	N/A	N/A	N/A	-520.90%	N/A	-202.73%	8/13/2025 (Estimated)
VERO Venus Concept	-$47M	-$76.30	N/A	∞	N/A	-81.26%	-752.29%	-54.52%	8/12/2025 (Estimated)

Latest CGIX, VERO, CERO, and PSTV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q1 2025	PSTV Plus Therapeutics	-$0.17	-$0.56	-$0.39	-$1.19	$1.11 million	$1.06 million
5/15/2025	N/A	CERO CERo Therapeutics	N/A	-$31.80	N/A	-$1.59	N/A	N/A
5/15/2025	Q1 2025	VERO Venus Concept	-$14.08	-$17.44	-$3.36	-$17.44	$14.59 million	$13.64 million
3/31/2025	Q4 2024	VERO Venus Concept	-$10.0089	-$11.23	-$1.2211	-$11.23	$16.99 million	$15.77 million
3/27/2025	Q4 2024	PSTV Plus Therapeutics	-$0.51	-$0.67	-$0.16	-$0.67	$1.19 million	$1.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	N/A
CGIX Cancer Genetics	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	N/A
VERO Venus Concept	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERO CERo Therapeutics	N/A	0.73	0.73
CGIX Cancer Genetics	N/A	N/A	N/A
PSTV Plus Therapeutics	N/A	1.03	1.03
VERO Venus Concept	7.91	1.28	0.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERO CERo Therapeutics	29.64%
CGIX Cancer Genetics	8.92%
PSTV Plus Therapeutics	3.28%
VERO Venus Concept	87.41%

Insider Ownership

Company	Insider Ownership
CERO CERo Therapeutics	12.72%
CGIX Cancer Genetics	15.00%
PSTV Plus Therapeutics	3.76%
VERO Venus Concept	28.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERO CERo Therapeutics	8	390,000	337,000	N/A
CGIX Cancer Genetics	N/A	4.09 million	N/A	Not Optionable
PSTV Plus Therapeutics	20	17.00 million	16.36 million	Not Optionable
VERO Venus Concept	410	1.42 million	1.03 million	Not Optionable

CGIX, VERO, CERO, and PSTV Headlines

Recent News About These Companies

Venus Concept Inc News (VERO) - Investing.com

June 26 at 6:05 PM | investing.com

Venus Concept Inc. (NASDAQ:VERO) Sees Significant Drop in Short Interest

June 17, 2025 | americanbankingnews.com

Venus Concept Stock Climbs After Stock Offering Closes

June 9, 2025 | marketwatch.com

Venus Concept Inc. Closes Registered Direct Offering and Private Placement Raising Approximately $1.15 Million

June 9, 2025 | quiverquant.comQ

Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

June 9, 2025 | globenewswire.com

Venus Concept To Sell Hair Business To Meta Healthcare In $20M All-Cash Deal

June 8, 2025 | nasdaq.com

Venus Concept prices $3.45M in direct offering, warrants; shares up over 29%

June 7, 2025 | msn.com

Venus Concept Stock Is Soaring On Friday - Here's Why

June 7, 2025 | aol.comA

Venus Concept Sells Hair Business to Meta Healthcare

June 6, 2025 | tipranks.com

Venus Concept Stock Is Soaring On Friday - Here's Why

June 6, 2025 | benzinga.com

Venus Concept Inc.: Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

June 6, 2025 | finanznachrichten.de

Venus Concept Shares Soar on Sale of Hair Business

June 6, 2025 | marketwatch.com

Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

June 6, 2025 | globenewswire.com

Venus Concept Inc. Sells Venus Hair Business to Meta Healthcare Group in $20 Million Deal

June 6, 2025 | quiverquant.comQ

Venus Concept to sell Venus Hair business for $20M, stock soars 50%

June 6, 2025 | msn.com

Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

June 6, 2025 | globenewswire.com

Venus Concept Announces First Quarter 2025 Financial Results

May 16, 2025 | theglobeandmail.com

Venus Concept Inc (VERO) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines Amid ...

May 16, 2025 | finance.yahoo.com

Venus Concept Inc. (NASDAQ:VERO) Q1 2025 Earnings Call Transcript

May 16, 2025 | msn.com

Venus Concept Inc. (VERO) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGIX, VERO, CERO, and PSTV Company Descriptions

CERo Therapeutics NASDAQ:CERO

$10.68 -0.51 (-4.56%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$10.65 -0.03 (-0.29%)

As of 08:00 AM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Cancer Genetics NASDAQ:CGIX

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

Plus Therapeutics NASDAQ:PSTV

$0.37 +0.05 (+16.38%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.31 -0.06 (-16.26%)

As of 08:02 AM Eastern

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Venus Concept NASDAQ:VERO

$2.20 +0.02 (+0.92%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.27 +0.07 (+3.14%)

As of 04:21 AM Eastern

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time